Daily Archives: December 11, 2025

NiKang Therapeutics® Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025

See the press release on Business Wire